Skip to main navigation Skip to search Skip to main content

A DNA-PKcs mutation in a radiosensitive T-B- SCID patient inhibits Artemis activation and nonhomologous end-joining

  • Mirjam Van Der Burg
  • , Hanna IJspeert
  • , Nicole S. Verkaik
  • , Tuba Turul
  • , Wouter W. Wiegant
  • , Keiko Morotomi-Yano
  • , Pierre Olivier Mari
  • , Ilhan Tezcan
  • , David J. Chen
  • , Malgorzata Z. Zdzienicka
  • , Jacques J.M. Van Dongen
  • , Dik C. Van Gent
  • Erasmus University Rotterdam
  • Hacettepe University
  • Leiden University
  • University of Texas Southwestern Medical Center
  • Nicolaus Copernicus University in Toruń

Research output: Contribution to journalArticlepeer-review

240 Citations (Scopus)

Abstract

Radiosensitive T-B- severe combined immunodeficiency (RS-SCID) is caused by defects in the nonhomologous end-joining (NHEJ) DNA repair pathway, which results in failure of functional V(D)J recombination. Here we have identified the first human RS-SCID patient to our knowledge with a DNA-PKcs missense mutation (L3062R). The causative mutation did not affect the kinase activity or DNA end-binding capacity of DNA-PKcs itself; rather, the presence of long P-nucleotide stretches in the immunoglobulin coding joints indicated that it caused insufficient Artemis activation, something that is dependent on Artemis interaction with autophosphorylated DNA-PKcs. Moreover, overall end-joining activity was hampered, suggesting that Artemis-independent DNA-PKcs functions were also inhibited. This study demonstrates that the presence of DNA-PKcs kinase activity is not sufficient to rule out a defect in this gene during diagnosis and treatment of RS-SCID patients. Further, the data suggest that residual DNA-PKcs activity is indispensable in humans.

Original languageEnglish
Pages (from-to)91-98
Number of pages8
JournalJournal of Clinical Investigation
Volume119
Issue number1
DOIs
Publication statusPublished - 5 Jan 2009

Fingerprint

Dive into the research topics of 'A DNA-PKcs mutation in a radiosensitive T-B- SCID patient inhibits Artemis activation and nonhomologous end-joining'. Together they form a unique fingerprint.

Cite this